Business Context and Reporting Period
This Form 8-K Current Report was filed by NanoViricides, Inc. on September 27, 2007, reporting events that occurred on September 21, 2007. The filing details a material definitive agreement involving the sale of equity securities to raise capital.
Key Financial Metrics and Transaction Details
The filing describes a private placement transaction rather than providing standard periodic financial statements (revenue, profit, cash flow). Key transaction metrics include:
- Total Proceeds: $750,000
- Common Stock Issued: 1,500,000 shares
- Warrants Issued: Warrants to purchase 450,000 shares
- Warrant Exercise Price: $1.00 per share
- Warrant Expiration: Three years from issuance
The filing text does not provide clear values for the company's current revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes and Agreements
The primary material change is the entry into a Subscription Agreement and a Registration Rights Agreement with DKR Saturn Event Driven Holding Fund Ltd. (the "Investor").
- Registration Rights: The company agreed to file a registration statement with the SEC by December 20, 2007, covering the resale of the shares and warrant shares.
- Effectiveness Deadline: The company must use best efforts to have the registration statement declared effective by March 19, 2008.
- Penalty for Delay: If the registration statement is not filed or declared effective within the specified timeframes, the company must issue additional warrants to the Investor. These penalty warrants cover 75,000 shares at an exercise price of $0.15 for each 30-day period of default.
Outlook, Risks, and Unusual Items
Regulatory Compliance: The securities were sold in reliance on exemptions from registration under Section 4(2) of the Securities Act and Rule 506. The Investor represented that they are an "accredited investor" and acquired the securities for their own account.
Restrictions: The issued securities are deemed "restricted securities" and bear legends indicating they cannot be resold or offered in the United States without registration or an applicable exemption.
Risks: The primary risk identified is the potential dilution of existing shareholders if the company fails to meet the registration statement deadlines, triggering the issuance of additional warrants at a significantly lower exercise price ($0.15).
Investor Verification Checklist
- Verify the status of the registration statement filing deadline (December 20, 2007) and effectiveness deadline (March 19, 2008).
- Confirm whether any penalty warrants have been issued due to delays in the registration process.
- Review the company's most recent 10-K or 10-Q filings to assess current liquidity and cash burn rates, as this 8-K does not contain operational financial data.
- Assess the impact of the 1,500,000 new shares and potential 450,000 warrant shares on existing shareholder dilution.